Celyad Oncology SA
F:1C0
Income Statement
Earnings Waterfall
Celyad Oncology SA
Income Statement
Celyad Oncology SA
| Jun-2013 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
4
N/A
|
4
+1%
|
3
-13%
|
3
+1%
|
1
-81%
|
0
-99%
|
0
+83%
|
0
-55%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+132%
|
0
-29%
|
0
+158%
|
0
N/A
|
|
| Gross Profit | |||||||||||||||||||
| Cost of Revenue |
(3)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Gross Profit |
(3)
N/A
|
3
N/A
|
3
+2%
|
3
-15%
|
3
+21%
|
1
-81%
|
0
-99%
|
0
+83%
|
0
-55%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+15%
|
0
+358%
|
0
+1%
|
|
| Operating Income | |||||||||||||||||||
| Operating Expenses |
(3)
|
(17)
|
(30)
|
(61)
|
(41)
|
(36)
|
(29)
|
(29)
|
(17)
|
(15)
|
(26)
|
(26)
|
(6)
|
(31)
|
(10)
|
(8)
|
(6)
|
(7)
|
|
| Selling, General & Administrative |
(1)
|
(4)
|
(9)
|
(10)
|
(10)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
(10)
|
(11)
|
(10)
|
(8)
|
(6)
|
(4)
|
(3)
|
(3)
|
|
| Research & Development |
(1)
|
(10)
|
(21)
|
(22)
|
(23)
|
(24)
|
(24)
|
(22)
|
(20)
|
(20)
|
(19)
|
(20)
|
(18)
|
(10)
|
(4)
|
(3)
|
(3)
|
(3)
|
|
| Depreciation & Amortization |
0
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
|
| Other Operating Expenses |
(1)
|
(1)
|
3
|
(27)
|
(7)
|
(2)
|
5
|
4
|
14
|
14
|
4
|
7
|
24
|
(12)
|
1
|
0
|
0
|
0
|
|
| Operating Income |
(6)
N/A
|
(14)
-127%
|
(27)
-94%
|
(58)
-118%
|
(38)
+34%
|
(36)
+7%
|
(29)
+19%
|
(29)
-1%
|
(17)
+42%
|
(15)
+10%
|
(26)
-72%
|
(26)
+3%
|
(6)
+77%
|
(31)
-429%
|
(10)
+69%
|
(8)
+18%
|
(6)
+25%
|
(6)
-10%
|
|
| Pre-Tax Income | |||||||||||||||||||
| Interest Income Expense |
(0)
|
(1)
|
(3)
|
(2)
|
0
|
1
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
|
| Non-Reccuring Items |
0
|
0
|
(26)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
(35)
|
0
|
1
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(6)
N/A
|
(14)
-125%
|
(56)
-291%
|
(60)
-7%
|
(37)
+38%
|
(35)
+7%
|
(29)
+18%
|
(29)
-2%
|
(17)
+41%
|
(15)
+10%
|
(27)
-71%
|
(26)
+3%
|
(41)
-59%
|
(31)
+25%
|
(9)
+72%
|
(8)
+8%
|
(6)
+25%
|
(6)
-11%
|
|
| Net Income | |||||||||||||||||||
| Tax Provision |
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(6)
|
(14)
|
(56)
|
(60)
|
(37)
|
(35)
|
(29)
|
(29)
|
(17)
|
(15)
|
(27)
|
(26)
|
(41)
|
(31)
|
(8)
|
(8)
|
(6)
|
(6)
|
|
| Net Income (Common) |
(6)
N/A
|
(14)
-125%
|
(56)
-291%
|
(60)
-7%
|
(37)
+38%
|
(35)
+7%
|
(29)
+18%
|
(29)
-2%
|
(17)
+41%
|
(15)
+10%
|
(27)
-71%
|
(26)
+3%
|
(41)
-59%
|
(31)
+25%
|
(8)
+72%
|
(8)
+8%
|
(6)
+25%
|
(6)
-11%
|
|
| EPS (Diluted) |
-2.5
N/A
|
-1.52
+39%
|
-5.86
-286%
|
-5.85
+0%
|
-3.36
+43%
|
-2.92
+13%
|
-2.29
+22%
|
-2.09
+9%
|
-1.23
+41%
|
-1.06
+14%
|
-1.7
-60%
|
-1.13
+34%
|
-1.81
-60%
|
-1.33
+27%
|
-0.33
+75%
|
-0.18
+45%
|
-0.14
+22%
|
-0.16
-14%
|
|